Fig. 2From: Intravitreal sirolimus with adjunct aflibercept versus aflibercept monotherapy for persistent, exudative age-related macular degeneration: a pilot studyMean change in BCVA from baseline (95% C.I.). This graph depicts the change in BCVA from baseline to 36-week visit. The average change from baseline for the treatment group was 2.5 letters (− 0.7, 5.7). The average change from baseline for the control group was 0.8 letters (− 1.3, 2.9)Back to article page